Clinical trials
PSMA Positive Tumors or Tumor Tissues clinical trials
Below are recruiting psma positive tumors or tumor tissues clinical trials, each written for real people, not researchers. We’re tracking 1,296 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06092086RecruitingPhase 2
Lorlatinib for first-line treatment of ALK-positive lung cancer
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
Guangzhou, GuangdongAges 18 years+ - NCT06074692RecruitingPhase 2
PARP inhibitor, SBRT, and immunotherapy for advanced sarcoma
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 10–70 - NCT06136845Recruiting
Esophageal cancer microbiome and leak after surgery
This study looks at bacteria in esophageal cancer tumors and whether certain bacteria are linked to leaks that can happen after surgery to remove the esophagus. It may help doctors understand how to prevent these leaks in the future.
HaifaAges 18–85 - NCT06147570RecruitingPhase 2
Study of HS-10365 for RET fusion-positive lung cancer
This trial tests an experimental drug called HS-10365 for people with advanced or metastatic non-small cell lung cancer that has a specific genetic change called a RET fusion. The drug aims to block the growth of cancer cells with this mutation.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04428528Recruiting
Ultrasound-like pictures that track breast tumors during chemotherapy
This study uses a special light-based imaging scan to learn more about breast masses and how tumors may respond to chemotherapy before surgery. The scan is meant to help doctors better characterize tumors and potentially track treatment response.
Toronto, OntarioAges Any age - NCT05851365RecruitingEarly Phase 1
MRI scan to measure prostate acidity before surgery
This study tests a new MRI technique that measures acidity in prostate tumors. It may help doctors better understand the cancer before surgery, potentially guiding treatment decisions.
San Francisco, CaliforniaAges 18 years+ - NCT07864870Recruiting
Sarcoma treatment adherence and survival study
This study looks at how closely patients in the Strasbourg area follow their sarcoma treatment plans and how that affects their survival. Sarcoma is a rare type of cancer that starts in the body's connective tissues, like fat, muscle, or blood vessels.
StrasbourgAges 18 years+ - NCT06215950RecruitingPhase 1
CAR-T cell therapy for advanced gynecologic cancer with CD70 protein
This trial tests a new treatment called CAR-T cells that target a protein called CD70 found on some gynecologic cancer cells. It is for people whose cancer has advanced or spread and has not responded to or stopped responding to standard treatments.
Wuhu, AnhuiAges 18 years+ - NCT02925234RecruitingPhase 2
Basket trial of reused cancer drugs matched to tumor markers
This trial tests cancer drugs that are already approved for other cancers, chosen based on specific changes found in your tumor. It may help people whose cancer is growing despite standard treatment (or who no longer have standard options).
AlkmaarAges 18 years+ - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT07128199RecruitingPhase 3
Zipalertinib after surgery for early-stage lung cancer with uncommon EGFR mutations
This study tests whether taking zipalertinib after lung cancer surgery can help prevent the cancer from coming back in people whose tumors have uncommon EGFR gene changes. It is a pill taken daily after recovery from surgery.
Anchorage, AlaskaAges 18 years+ - NCT06228963RecruitingPhase 2
Orelabrutinib for H. pylori-positive gastric MALT lymphoma
This trial tests a targeted drug called orelabrutinib for people with a specific type of stomach lymphoma that is linked to an active H. pylori infection. The goal is to see if the drug can help shrink or control the lymphoma.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06215495Recruiting
New radiation target method for high-grade glioma
This study is testing a new way to target radiation for people with high-grade gliomas (aggressive brain tumors). The goal is to see if a more precise treatment plan can improve outcomes while keeping side effects low.
GuangzhouAges 18–65 - NCT06276088Recruiting
SAA1 levels to predict cancer immunotherapy response
This trial measures a protein called SAA1 in your blood and tumor tissue to see if it can predict how your cancer will respond to immunotherapy. It aims to understand why some patients have rapid tumor growth after treatment.
Guangzhou, GuangdongAges 18 years+ - NCT05280314RecruitingPhase 2
Immunotherapy before and after surgery for stage III melanoma or throat cancer
This trial tests two immunotherapy medicines given before surgery and again after surgery to help control the cancer and improve outcomes. It studies people with resectable (operable) stage III melanoma or certain stage III/IVA throat cancers.
New Haven, ConnecticutAges 18 years+ - NCT06327997RecruitingEarly Phase 1
Fast CAR-T cells for advanced solid tumors
This trial tests a new type of 'fast CAR-T' cell therapy for people with advanced solid tumors that have not been helped by standard treatments. CAR-T cells are a kind of immune cell that is reprogrammed to attack cancer cells that carry certain markers called mesothelin, MUC1, and PD-L1.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT03767075RecruitingPhase 2
Basket trial matching cancer patients to targeted treatments
This trial tests whether matching your tumor’s DNA/RNA results to a specific cancer medicine can work better than standard options when cancer has spread or can’t be removed by surgery. You may be assigned to a “basket” (sub-study) based on the exact changes found in your tumor.
VillejuifAges 18 years+ - NCT06300177RecruitingPhase 3
New targeted pill vs. chemotherapy for KRAS G12C lung cancer
This trial compares a new targeted pill (D-1553) against a standard chemotherapy (docetaxel) for people with a specific type of advanced lung cancer (KRAS G12C mutation) whose cancer has stopped responding to first-line immunotherapy and chemotherapy.
Hefei, AnhuiAges 18 years+ - NCT06389006RecruitingPhase 2
Combination therapy before surgery for HER2-low, hormone-positive breast cancer
This trial tests a combination of two drugs (disitamab vedotin and toripalimab) followed by chemotherapy before surgery for people with a specific type of breast cancer that is hormone receptor-positive and HER2-low. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Shanghai, Fudan University Shanghai Cancer CenterAges 18 years+ - NCT05266846RecruitingPhase 2
Immunotherapy plus anti-angiogenesis and chemo for ALK lung cancer
This Phase 2 trial tests pembrolizumab (an immune therapy), bevacizumab (a medicine that blocks blood-vessel growth), and chemotherapy in people with ALK-rearranged lung cancer that is still present after the first treatment with alectinib. It aims to shrink tumors and improve control of the cancer.
Changsha, HunanAges 18 years+ - NCT03979170Recruiting
Test lung cancer drug response using patient tumor mini-organs
This trial grows “organoids” (mini tumor models) from your lung cancer tissue to see which drug responses are most likely. It may help match future treatments to how your tumor behaves in the lab.
GenevaAges 18 years+ - NCT06440902RecruitingPhase 2
New treatments for RAS-changed colorectal cancer using blood tests
This study tests new treatment plans for people with metastatic colorectal cancer whose tumors originally had a RAS mutation but later show no RAS mutation in blood tests. The goal is to see if these treatment changes can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07849608Recruiting
AI Tool to Assess Tumor Response After Pre-Surgery Treatment
This study is testing an AI tool (DeepTRG) that looks at tissue samples after pre-surgery treatment to see how well the tumor responded. It may help doctors better understand whether the treatment worked.
Shijiazhuang, None SelectedAges 18 years+ - NCT06451393Recruiting
AI predicts stomach cancer response to chemo
This trial tests a computer-based model that uses CT scans, endoscopic images, and biopsy tissue to predict how well stomach cancer will respond to chemotherapy given before surgery. The goal is to help doctors choose the best treatment for each patient.
Guangzhou, GuangdongAges 20–90
Hear when a new PSMA Positive Tumors or Tumor Tissues trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psma positive tumors or tumor tissues?
- Yes. Clin2 currently lists 1,296 recruiting psma positive tumors or tumor tissues studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psma positive tumors or tumor tissues trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psma positive tumors or tumor tissues trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.